Healthcare Providers and Services
Company Overview of Aspen Global Incorporated
Aspen Global Incorporated operates as the holding company for the Aspen Group’s international businesses that manages and maintains the intellectual property rights, and regulatory and commercialization strategies of a portfolio of specialist and branded products. The company also performs procurement, distribution, and supply related operations. Its product portfolio comprises products for various therapeutic categories, such as anti-infective, cardiovascular and central nervous systems, hematology/oncology, hypothyroidism, immune system, metabolic diseases, and nonsteroidal anti-inflamatory drugs. The company was founded in 2008 and is based in Grand Baie, Mauritius. It has businesses in S...
301 GBS Plaza
cnr La Salette and Royal Roads
Founded in 2008
230 269 1111
230 269 1112
Key Executives for Aspen Global Incorporated
Compensation as of Fiscal Year 2016.
Aspen Global Incorporated Key Developments
AstraZeneca PLC Completes Commercialization Agreement with Aspen Global Incorporated for Anaesthetics Portfolio
Sep 1 16
AstraZeneca PLC announced that it has completed the commercialization agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest).
Astrazeneca Enters into Commercialization Agreement with Aspen Global Incorporated for Rights to its Global Anaesthetics Portfolio Outside the US
Jun 9 16
AstraZeneca announced it has entered into a commercialization agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). Under the terms of the agreement, AGI will acquire the commercialization rights, outside the US, to AstraZeneca's portfolio of anaesthetic medicines for an upfront consideration of $520 million. Additionally, AGI will pay AstraZeneca up to $250 million in a Product Sales-related payment, as well as double-digit percentage trademark royalties on Product Sales. AstraZeneca will manufacture and supply the products on a cost plus basis to AGI for an initial period of 10 years. Upon completion, Aspen will assume responsibility for all activities relating to the sale of the portfolio in all relevant markets.
Aspen Global Incorporated to Launch the Finished Dose Form Product Indicated for the Treatment of Certain Female Cancers and Hormonal Imbalances
Feb 19 16
Aspen Global Incorporated had acquired the intellectual property and the approved Abbreviated New Drug Application in the United States in respect of the finished dose form of Hydroxyprogesterone Caproate. Aspen announced that AGI expects to launch the finished dose form product, indicated for the treatment of certain female cancers and hormonal imbalances, in the United States during its current financial year which ends on 30 June 2016. Aspen is in advanced negotiations with a United States pharmaceutical company with proven capabilities in this category to distribute the HPC finished dose form. Aspen currently manufactures the active pharmaceutical ingredient for HPC and is a substantial supplier of HPC API to the United States. Aspen's launch of HPC injection is a realisation of Aspen's stated intent to develop commercial opportunities in the United States which are aligned to the intellectual property available within the Group.
Similar Private Companies By Industry
Recent Private Companies Transactions